Last Updated : May 8, 2024
Details
Generic Name:
etrasimod
Project Status:
Active
Therapeutic Area:
Ulcerative colitis
Manufacturer:
Pfizer Canada ULC
Call for patient/clinician input open:
Brand Name:
Velsipity
Project Line:
Reimbursement Review
Project Number:
SR0795-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | December 08, 2023 |
|---|---|
| Call for patient/clinician input closed | February 12, 2024 |
| Clarification: - Patient input submission received from Crohn's and Colitis Canada and Gastrointestinal Society | |
| Submission received | February 05, 2024 |
| Submission accepted | February 20, 2024 |
| Review initiated | February 21, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | May 14, 2024 |
| Deadline for sponsors comments | May 24, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | June 14, 2024 |
| Expert committee meeting (initial) | June 26, 2024 |
| Draft recommendation issued to sponsor | July 09, 2024 To July 11, 2024 |
| Draft recommendation posted for stakeholder feedback | July 19, 2024 |
| End of feedback period | August 02, 2024 |
Last Updated : May 8, 2024